General
Preferred name
GSK256073
Synonyms
GSK-256073 ()
P&D ID
PD049790
CAS
862892-90-8
Tags
available
drug candidate
Drug indication
Hyperlipidaemia
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION GSK256073 is a potent, selective and orally active GPR109A agonist and a long-lasting and non-flushing HCA2 full agonist with a pEC50 of 7.5 (human HCA2). GSK256073 acutely improves glucose homeostasis via inhibition of lipolysis and has the potential for the study of type 2 diabetes mellitus (T2DM)and dyslipidemia[1][2]. GPR109A: G-protein coupled receptor 109A; HCA2: hydroxy-carboxylic acid receptor 2
PRICE 165
DESCRIPTION GSK256073 is an orally active GPR109A agonist. GSK256073 also is a long-lasting and non-flushing HCA2 (hydroxy-carboxylic acid receptor 2) full agonist (pEC50: 7.5). GSK256073 acutely improves glucose homeostasis via inhibition of lipolysis. (TargetMol Bioactive Compound Library)
Compound Sets
9
Concise Guide to Pharmacology 2017/18
8470
Concise Guide to Pharmacology 2019/20
8470
Concise Guide to Pharmacology 2021/22
8470
Concise Guide to Pharmacology 2023/24
8470
DrugMAP
DMMAIY2
Guide to Pharmacology
8470
MedChem Express Bioactive Compound Library
HY-119222
ReFrame library
TargetMol Bioactive Compound Library
T15432
External IDs
14
Properties
(calculated by RDKit )
Molecular Weight
256.07
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
2
Rotatable Bonds
4
Ring Count
2
Aromatic Ring Count
2
cLogP
1.26
TPSA
83.54
Fraction CSP3
0.5
Chiral centers
0.0
Largest ring
6.0
QED
0.64
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Target
GPR109A
HCA2 (hydroxy-carboxylic acid receptor 2)
Pathway
GPCR/G protein
Endocrinology/Hormones
Source data